Endocrinology-Hormones

RORγt inverse agonist 36 is a selective inverse agonist targeting the retinoid-related orphan receptor gamma t (RORγt). This compound modulates RORγt activity, leading to inhibition of Th17 cell differentiation and cytokine production. It is primarily utilized in research focused on inflammation and immunology, offering valuable insights into therapeutic approaches for autoimmune diseases.

CID 7309015 is a selective inhibitor of retinoic acid-related orphan receptor gamma (ROR-γ). This compound demonstrates significant potential in modulating inflammatory pathways, particularly in the context of NF-κB signaling and inflammatory arthritis research. CID 7309015 serves as a valuable tool for investigating the roles of ROR-γ in immune response and inflammatory diseases.

RORγt inhibitor 3 is a potent and orally active inhibitor of retinoic acid receptor-related orphan receptor-gamma-t (RORγt), which plays a crucial role in Th17 cell differentiation. This compound demonstrates high binding affinity and effectively modulates immune responses, making it particularly relevant for research in autoimmune disorders. Its efficacy has been validated in mouse models of experimental autoimmune encephalomyelitis (EAE) and collagen-induced arthritis (CIA), highlighting its potential for therapeutic applications in inflammatory diseases.

CIDD 0067106 is a selective inhibitor of the mTORC1 pathway, specifically designed for targeting androgen receptor-positive (AR+) triple-negative breast cancer (TNBC). It exhibits potent activity against AR+ TNBC cell lines, with a GI50 value of 0.8 μM, indicating its effectiveness in inhibiting cancer cell proliferation. This compound is valuable for research focused on understanding and developing treatments for AR+ TNBC.

4,4'-Oxydiphenol is a known estrogen receptor inhibitor, exhibiting an IC50 value of 60 μM. This compound manifests significant biological activity by modulating estrogen signaling pathways, making it a useful tool for exploring estrogen receptor-related mechanisms. It is pertinent for research applications in cancer biology, particularly in studies focused on hormone-dependent tumors and endocrine regulation.

VPC-16606 is a selective inhibitor of the estrogen receptor alpha (ERα), specifically targeting its activation function 2 (AF2) domain. This compound effectively disrupts the interaction between ERα and coactivators, inhibiting the activity of both wild-type and drug-resistant mutant forms of ERα. VPC-16606 demonstrates significant potency against hormone-resistant breast cancer cells, making it a valuable tool for research in breast cancer mechanisms and therapeutic development.

Millewanin G is a prenylated isoflavonoid that acts as an estrogen-related receptor (ERR) inhibitor, exhibiting antiestrogenic activity with an IC50 of 29 μM. This compound is primarily isolated from the leaves of M. pachycarpa, which is cultivated in Japan. Millewanin G is valuable for research applications focused on understanding ERR's role in various biological processes and its impact on diseases influenced by estrogen signaling.

ERRγ-IN-1 is a potent ERRγ inhibitor with an IC50 of 0.040 μM. It demonstrates activation of the MAPK (p44/p42) pathway while effectively inhibiting ERRγ activity. ERRγ-IN-1 has been shown to enhance iodine uptake in anaplastic thyroid carcinoma xenografts and to suppress tumor growth in nude mouse models. This compound is valuable for research focused on anaplastic thyroid carcinoma.

Yp537 is an estrogen receptor inhibitor that disrupts the dimerization of the human estrogen receptor. This action effectively impedes estrogen-mediated signaling pathways, making it valuable for research on hormone-dependent cancers and other estrogen-related diseases. Yp537 is suitable for studying the molecular mechanisms underlying estrogen receptor activity and evaluating potential therapeutic strategies targeting these pathways.

OBHS is an inhibitor of estrogen receptor α (ERα), providing a crucial tool for studying estrogen signaling pathways. This compound is primarily utilized in research applications focusing on hormone-related cancers and endocrine disorders. Additionally, OBHS can function as a blowing agent, offering versatility for various chemical processes.

Estrogen Receptor Modulator 8 is a potent ERRα inhibitor, exhibiting an IC50 of 0.437 nM in MCF-7 cells. This compound effectively inhibits the proliferation of MCF-7 cells with an IC50 value of 0.1 nM. It serves as a valuable tool for studying estrogen receptor signaling pathways and their implications in cancer research.

Triisopropyl phosphate is an estradiol inhibitor that exerts anti-estrogenic activity by inhibiting TFF1 and EGR3 gene expression. It demonstrates the ability to suppress estradiol-induced proliferation in MCF-7 cells, with an EC50 of 341 μM. Additionally, it inhibits estrogen response element (ERE)-stimulated luciferase activity in MVLN cells with an EC50 of 900 μM, making it a valuable tool for research in estrogen signaling pathways.

Metahexestrol functions as an estrogen receptor (E2R) inhibitor, demonstrating significant antitumor activity. It effectively inhibits the proliferation of estrogen receptor-positive MCF-7 human breast cancer cells with an ED50 of 1.0 μM. Notably, Metahexestrol also shows inhibitory effects on estrogen receptor-negative MDA-MB-231 cells, indicating that its antiproliferative action may occur independently of the E2R pathway. This compound is valuable for research focused on estrogen-dependent breast cancer.

NR2F2-IN-1 free base is a selective inhibitor targeting the orphan nuclear receptor COUP-TFII (NR2F2). This compound effectively suppresses COUP-TFII-driven expression of the NGFIA reporter by binding to the ligand-binding domain of COUP-TFII, interfering with its interactions with transcriptional regulators such as FOXA1. NR2F2-IN-1 is suitable for research applications focused on elucidating the role of COUP-TFII in gene regulation and its implications in various biological processes.

SID 7969543 is a selective inhibitor of steroidogenic factor 1 (SF-1, NR5A1) with an IC50 value of 760 nM. This compound effectively inhibits SF-1-mediated luciferase expression with an impressive IC50 of 30 nM. SF-1 plays a crucial role as a transcription factor within the nuclear receptor superfamily, making SID 7969543 valuable for research involving steroidogenesis and related pathways.

SID7970631 is a selective inhibitor of Steroidogenic Factor-1 (SF-1), exhibiting potent activity with an IC50 of 255 nM. This isoquinolinone analog is primarily utilized in cancer research, facilitating the investigation of SF-1's role in tumorigenesis and potential therapeutic strategies. Its specificity and efficacy make SID7970631 a valuable tool for studying pathways associated with steroidogenesis and related malignancies.

NR2F2-IN-1 is a potent and selective inhibitor of the orphan nuclear receptor COUP-TFII (NR2F2). It significantly inhibits COUP-TFII-driven expression of the NGFIA reporter by directly binding to the ligand-binding domain of COUP-TFII, thereby disrupting its interactions with transcriptional regulators such as FOXA1. This inhibition effectively suppresses COUP-TFII activity on the regulation of target genes, making NR2F2-IN-1 a valuable tool for studying the role of COUP-TFII in various biological processes and diseases.

LRH-1 Inhibitor-3 is a small molecule that specifically inhibits the transcriptional activity of the orphan nuclear receptor LRH-1. By downregulating the expression of genes linked to cell growth and proliferation, this compound has demonstrated potential in reducing proliferation in human pancreatic, colon, and breast adenocarcinoma cell lines. LRH-1 Inhibitor-3 serves as a valuable molecular probe for exploring the role of LRH-1 in various cancer types and may provide insights into targeted cancer therapies.

Mifepristone methochloride is a selective progesterone receptor inhibitor. It functions as a glucocorticoid antagonist, effectively blocking peripheral glucocorticoid and progesterone receptors. This compound has demonstrated minimal effects on intraocular pressure in preclinical studies, making it suitable for research into ocular pharmacology. The water-soluble formulation of Mifepristone methochloride is designed to enhance drug penetration in ocular tissues, facilitating studies on its therapeutic potential in eye diseases.

CP8754 is a selective antagonist of the human progesterone receptor (hPR), acting primarily by competitively inhibiting the binding of [3H]-progesterone. This compound effectively impedes progesterone-mediated signaling, as evidenced by its ability to inhibit both exogenous luciferase and endogenous alkaline phosphatase expression in vitro, and to suppress rabbit endometrial transformation in vivo. CP8754 exhibits minimal binding affinity for human glucocorticoid receptors, estrogen receptors, and rat androgen receptors, making it a valuable tool for investigating progesterone-related diseases, including breast cancer, endometriosis, uterine fibroids, and hormone-dependent tumors.

Debutyldronedarone hydrochloride is a selective inhibitor of the thyroid hormone receptor α1 (TRα1), derived from the main metabolite of Dronedarone. This compound effectively inhibits T3 binding to TRα1 and TRβ1 by 77% and 25%, respectively. It is primarily utilized in research related to arrhythmic conditions, providing insights into the mechanisms of thyroid hormone signaling in cardiac physiology.

Glp-Asn-Pro-AMC is a selective inhibitor of thyrotropin-releasing hormone degrading enzyme (TRH-DE), exhibiting a Ki value of 0.97 μM. This compound is valuable for studying the role of TRH-DE in metabolic and neuroendocrine regulation. Its inhibitory action on TRH-DE makes it a useful tool in research related to thyroid hormone regulation and potential therapeutic interventions in conditions impacted by TRH signaling.

L-6424 is a selective inhibitor of triiodothyronine receptor (T3R) binding, specifically targeting alpha-1 (α1-T3R) and beta-1 (β1-T3R) receptors. Its primary mechanism interferes with T3 binding, making it a useful tool in research focused on thyroid hormone signaling pathways. This compound is applicable in studies investigating the role of T3R in metabolic regulation, cellular differentiation, and various endocrine disorders.

A 274 is a thyroid hormone receptor inhibitor that functions as an analogue of amiodarone. It effectively inhibits the binding of triiodothyronine (T3) to both α1- and β1-thyroid hormone receptors in vitro, demonstrating significant potential for modulating thyroid hormone signaling. This compound can be utilized in research applications focused on thyroid function and its associated biochemical pathways.

(R)-Acenocoumarol is a vitamin K epoxide reductase inhibitor, serving as a potent orally active anticoagulant. It exhibits superior in vivo anticoagulant potency compared to Warfarin, attributed to its longer plasma elimination half-life and slower plasma clearance rate. This compound is particularly valuable in research applications focused on coagulation studies and the pharmacodynamics of anticoagulants. Its unique chiral center allows for exploration into the distinct biological activities of its enantiomeric forms.

Pefcalcitol, a phosphodiesterase inhibitor, exhibits potential as a therapeutic agent for psoriasis management. Its unique 16-en-22-oxa-vitamin D3 structure contributes to its biological activity, influencing cellular signaling pathways associated with skin inflammation and proliferation. This reagent is instrumental in pharmacological research aimed at understanding psoriasis pathophysiology and developing innovative treatment strategies.